Back to today’s briefing

Story perspectives

Investors Probe Capricor Therapeutics for Possible Securities Fraud

7/15/2025

50 11

Summary

Story summary

Shamis & Gentile P.A. is probing possible securities fraud involving Capricor Therapeutics Inc. (CAPR) following the FDA's rejection of its key therapy, deramiocel. Investors who faced losses from September 24, 2024, to July 11, 2025, can confidentially join the investigation at no cost, with the chance for compensation if a lawsuit emerges.

1 of 1

Story summary

Shamis & Gentile P.A. is probing possible securities fraud involving Capricor Therapeutics Inc. (CAPR) following the FDA's rejection of its key therapy, deramiocel. Investors who faced losses from September 24, 2024, to July 11, 2025, can confidentially join the investigation at no cost, with the chance for compensation if a lawsuit emerges.